Galena Biopharma links with and Dr Reddy's for NeuVax in India

USA-based Galena Biopharma (Nasdaq: GALE) and India’s second-largest drugmaker Dr Reddy's Laboratories (NYSE: RDY) have entered a strategic development and commercialization partnership on NeuVax (nelipepimut-S) in India.

Under the terms of the deal, Dr Reddy's will lead the development of NeuVax in gastric cancer, significantly expanding the potential addressable patient population, said Galena, which will receive development and sales milestones, as well as double-digit royalties on net sales from the Indian firm.

"This partnership with Dr Reddy's is consistent with our strategy to expand the clinical utility of NeuVax in unmet medical needs while simultaneously increasing the commercial footprint of this innovative cancer immunotherapy," said Mark Ahn, president and chief executive of Galena, adding that "the gastric cancer trial will add a significant indication to our pipeline for NeuVax, while doubling our potential patient population if approved."